Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 6Unknown 2Terminated 2Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 42CNS 37Genitourinary 33Thoracic 28Breast 28Head & Neck 19Lymphoid 18Sarcoma 17Dermatologic 10Gynecologic 8Other solid neoplasm 4Tumor-Agnostic 3Plasma cell 2Other hematologic neoplasm 2Other neoplasm 1NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Carcinoma, Merkel Cell 1Carcinoma 1

Interventions

lutetium Lu 177 dotatate 14Nivolumab 12Magnetic Resonance Spectroscopy 11pembrolizumab 10Specimen Handling 10Ipilimumab 9cabozantinib 8trametinib 6lenvatinib 6Temozolomide 6dabrafenib 4atezolizumab 4Lutetium-177 4Immunoglobulin G 4Everolimus 4Disulfides 4CTLA-4 Antigen 4selpercatinib 3Octreotide 3Cisplatin 3Carboplatin 3Capecitabine 3Bevacizumab 3entrectinib 2copper dotatate CU-64 2avelumab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Vemurafenib 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Radiotherapy × Endocrine × Clear all
NCT04261855 2026-03-27

GoTHAM

Melanoma and Skin Cancer Trials Limited

Phase 1/2 Active not recruiting
19 enrolled
DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡